Probiotic V9 in Advanced GI Cancer Chemotherapy Patients
96 gut metagenome samples from adults with advanced gastric or esophageal cancer, studying Bifidobacterium animalis subsp. lactis V9 probiotic supplementation during chemotherapy, in a randomized, double-blind, placebo-controlled design. machine-written summary
183 samples · 183 runs · CN · Adult · 2026 · 7.94 Gbp / sample
Checked this project's papers and archive records yourself? Mark it human-verified.
what each source gave
| ✓ Sequence archive | 375 sample values (collection date, subject id, timepoint) |
| ○ Abstract / description | read; no usable statement |
| ✓ Full text | 636 sample values (collection date, country, health condition, health condition detail) · PMC13362969 |
| ○ Supplementary tables | files read; no table could be matched to the samples |
| – External resources | not covered by the external resources we ingest |
| – User contribution | nothing uploaded yet |
| – Human verified | not yet checked by a person · I checked this project — verify it |
intervention — arms not resolved
Probiotic (live microorganisms; single strain or mixture) design randomized_controlled_trial · population other_cancer · Bifidobacterium animalis subsp. lactis V9 probiotic vs placebo during chemotherapy
“randomized, double-blind, placebo-controlled design” — bioproject.description (study level; per-sample arms are in the intervention column below)
longitudinal — not resolved
85 of 98 people sampled more than once (170 samples; median 2, up to 2 per person). Schedule stated by the source: “stool at baseline (Week 0) and post-intervention (Week 18)” (time origin: baseline); stated follow-up 4 mo.
No Sandpiper profile for this project's samples yet.
| field | samples | coverage | R1 | R2 | R3 | R4 |
|---|---|---|---|---|---|---|
| age_category | 183 | 100% | ||||
| country | 183 | 100% | 183 | |||
| health_condition | 183 | 100% | 183 | |||
| subject_id | 183 | 100% | 183 | |||
| collection_date | 183 | 100% | 96 | 87 | ||
| health_condition_detail | 183 | 100% | 183 | |||
| timepoint_label | 96 | 52% | 96 |
- Bifidobacterium animalis subsp. lactis V9 improves quality of life in advanced gastrointestinal cancer through gut microbiota-metabolite modulation. 2026 PMID 42445733 PMC13362969 own_data
Archive description
Building on this rationale, the present study tests the hypothesis that V9 supplementation during chemotherapy improves quality of life in patients with advanced gastric or esophageal cancer by restoring gut microbial balance and modulating bioactive metabolite profiles. Using a randomized, double-blind, placebo-controlled design integrated with longitudinal metagenomic and metabolomic profiling, this work seeks to move beyond symptomatic assessment toward a mechanistic understanding of how a defined probiotic intervention influences the host-microbiota-metabolite axis. The findings aim to provide evidence-based support for the use of V9 as a safe and effective adjunctive therapy to enhance resilience, reduce treatment-related toxicity, and improve overall well-being in this vulnerable patient population.
How this project entered the registry
Classified as human gut / stool shotgun DNA metagenome of adult by deterministic_prior with confidence 0.90. Assay shotgun_dna.
- host external_curation.infant_catalog · “infant triage reason_code age_adult_only”
- body site study.title · “Life in Advanced Gastrointestinal Cancer Through Gut”
- body site study.description · “cancer by restoring gut microbial balance and”
- life stage external_curation.infant_catalog · “infant triage reason_code age_adult_only”
Evidence examples (one per field × route)
| sample | field | value | route | conf. | source | quote |
|---|---|---|---|---|---|---|
| SAMD01868583 | collection_date | 2024-06-03 | R1 | 0.90 | biosample.attribute:collection_date | 2024-06-03 |
| SAMD01868587 | collection_date | 2024-04/2025-03 | R3 | 0.70 | paper.body.methods_results | conducted over 18 weeks between April 2024 to March 2025 |
| SAMD01868583 | country | CN | R3 | 0.70 | paper.body.methods_results | Beijing Shijitan Hospital (affiliated with Capital Medical University) and Sichuan Cancer Hospital |
| SAMD01868583 | health_condition | other_cancer | R3 | 0.70 | paper.body.methods_results | histologically or cytologically confirmed advanced (stage IV) gastric and esophageal cancer |
| SAMD01868583 | health_condition_detail | advanced (stage IV) gastric and esophageal cancer | R3 | 0.70 | paper.body.methods_results | histologically or cytologically confirmed advanced (stage IV) gastric and esophageal cancer |
| SAMD01868583 | subject_id | A35 | R1 | 0.70 | sample.name_rule:title | A35-1 (SAMC6272688) |
| SAMD01868587 | subject_id | dz-A13 | R1 | 0.70 | sample.name_rule:TITLE | dz-A13-3 (SAMC6272692) |
| SAMD01868583 | timepoint_label | T1 | R1 | 0.70 | sample.name_rule:title | A35-1 (SAMC6272688) |
Sequencing
183 runs over 183 samples · mean 8.23 Gbp per run (median 7.94 Gbp, total 1,506.19 Gbp; 183 runs with a base count) · layout PAIRED 183 · platform ILLUMINA 183 · models Illumina NovaSeq 6000 (183) · 0% of runs with a Sandpiper profile · first public 2026-09-05
Authors (0)
No author record.
Downloads
PRJDB41979.csv.gz (5.3 KB) · parquet (76.7 KB) — all 183 samples, every field with route and confidence · PRJDB41979_determinations.csv.gz (9.4 KB) — 1,011 evidence rows